Malignant Germ Cell Tumor of the Ovary: Disease-Characteristics Report

Executive summary

Malignant ovarian germ-cell tumors (MOGCTs) are a heterogeneous group of rare, rapidly growing neoplasms derived from primordial germ-cell lineages. They predominantly affect children, adolescents, and young adults, most often presenting with acute or subacute abdominal pain and a rapidly enlarging adnexal mass. Major histologies are dysgerminoma, yolk-sac tumor (YST), immature teratoma, mixed germ-cell tumor, embryonal carcinoma, and nongestational choriocarcinoma. Unlike epithelial ovarian cancers, MOGCTs usually have a low point-mutation burden but marked chromosomal, imprinting, and DNA-methylation abnormalities. Fertility-sparing surgery and platinum-based chemotherapy cure most newly diagnosed patients; recurrent, platinum-resistant YST is the principal unmet clinical need. (pinto2023molecularbiologyof pages 4-6, saani2023clinicalchallengesin pages 2-3, pinto2023molecularbiologyof pages 1-3, pinto2023molecularbiologyof pages 16-18)

The following matrix summarizes the most transferable evidence.

Table: Compact evidence matrix summarizing the highest-yield disease, molecular, diagnostic, treatment, prognosis, relapse, and model findings for malignant ovarian germ cell tumors. It is useful for quickly transferring supported facts into a disease knowledge-base entry.

1. Disease information

Definition and classification

MOGCT is an umbrella disease category rather than one molecularly uniform cancer. It comprises malignant neoplasms showing germinoma-like, extraembryonic, embryonal, or somatic differentiation:

• Dysgerminoma—ovarian counterpart of testicular seminoma.
• Yolk-sac tumor/endodermal sinus tumor.
• Immature teratoma, graded by the amount of immature neuroepithelium.
• Mixed germ-cell tumor containing two or more malignant components.
• Embryonal carcinoma and nongestational choriocarcinoma, both very rare.
• Gonadoblastoma is a precursor/mixed lesion arising especially in dysgenetic gonads and can be overgrown by dysgerminoma.

Dysgerminoma and immature teratoma together account for approximately 65–70% of cases; YST accounts for about 14.5%, mixed tumors 5.3%, and embryonal carcinoma approximately 4%. Dysgerminoma alone represents roughly 35–50% of MOGCTs. (pinto2023molecularbiologyof pages 4-6, saani2023clinicalchallengesin pages 3-5, saani2023clinicalchallengesin pages 2-3)

A useful verbatim summary from the 2023 molecular review is: “OGCTs are rare tumors … [and] occur predominantly in children, adolescents, and young adults.” The same review stresses that few ovarian-specific molecular studies exist. (pinto2023molecularbiologyof pages 1-3)

Identifiers and synonyms

• Preferred label: malignant ovarian germ cell tumor; malignant germ cell tumor of ovary.
• Synonyms: ovarian germ-cell cancer, malignant ovarian germ-cell neoplasm, MOGCT, malignant OGCT.
• MeSH: Ovarian Germ Cell Cancer, MeSH supplementary concept C562841; broader term Ovarian Neoplasms, D010051. (NCT02429687 chunk 1, NCT02429687 chunk 2)
• ICD-10-CM: generally coded by site as C56.-, malignant neoplasm of ovary; morphology requires an oncology morphology system such as ICD-O-3.
• ICD-O-3: histology-specific morphology codes should be used—for example, dysgerminoma, yolk-sac tumor, immature teratoma, or mixed germ-cell tumor—together with ovarian topography C56.9.
• MONDO/Orphanet/OMIM: a single umbrella identifier was not verified in the retrieved primary literature. The individual histologies may have separate ontology entries. Curators should resolve the current MONDO and Orphanet release rather than assign an unverified identifier. OMIM is not the primary classification system for this mostly somatic cancer.

The report synthesizes aggregated disease-level literature and trial records, not individual EHR data. Some cited cohorts were retrospective patient-level studies, but no identifiable patient record was accessed.

2. Etiology, risk, and protective factors

Causal framework

Most cases are sporadic. The best-supported model is aberrant transformation of a primordial germ cell or oocyte-lineage cell during germ-cell specification, migration, gonadal colonization, meiosis, or epigenetic reprogramming. Pluripotency programs involving POU5F1/OCT3/4, NANOG, SOX2/SOX17, PRDM1, and PRDM14 remain active; subsequent copy-number changes, KIT–RAS signaling, lineage-specific methylation, and differentiation state determine histology. Immature teratomas appear particularly related to meiotic error and parthenogenetic/oocyte-like development rather than recurrent somatic driver mutations. (pinto2023molecularbiologyof pages 4-6, saani2023clinicalchallengesin pages 8-9)

Established genetic/developmental risk

The strongest recognized predisposition is a disorder/difference of sex development with a dysgenetic gonad and Y-chromosome material, especially the gonadoblastoma region of Y. In a 22-patient pediatric series, 6/22 (27.3%) had gonadal neoplasia. Rates were 4/6 (66.7%) in 46,XY complete gonadal dysgenesis, 1/10 (10%) in Turner syndrome with Y material, and 1/6 (16.6%) in androgen synthesis/action disorders. All tumors arose in streak-gonad tissue; gonadoblastoma and dysgerminoma predominated. Estimates are imprecise because cohorts are small and management practices differ. (lu2022gonadaltumorrisk pages 6-7, lu2022gonadaltumorrisk pages 1-2, lu2022gonadaltumorrisk pages 5-6)

Risk is enhanced by an intra-abdominal gonad, incomplete germ-cell maturation, expression of OCT3/4 and TSPY, and increasing age. A 2023 Swyer-syndrome report emphasized that primary amenorrhea and absent secondary sexual development should trigger DSD assessment even when imaging and serum markers are unrevealing. (sowinskaprzepiera2023latediagnosisof pages 1-2, piazza2019germcelltumors pages 1-2)

Environmental, lifestyle, infectious, and protective factors

No reproducible causal association with smoking, alcohol, diet, obesity, occupational toxins, pollution, radiation, or an infectious agent was established in the retrieved ovarian-specific literature. No validated protective germline allele, dietary intervention, medication, or vaccine is known. Complete androgen insensitivity may confer lower childhood malignant transformation risk than complete gonadal dysgenesis, but it should not be treated as a general protective factor; risk rises with age and remains management-dependent. (piazza2019germcelltumors pages 4-5, lanciotti2019differentclinicalpresentations pages 3-5)

Accordingly, no clinically validated gene–environment interaction has been established. Apparent references to carcinogen-related methylation are generic cancer biology and not evidence that a specific exposure causes MOGCT. (pinto2023molecularbiologyof pages 11-12)

3. Phenotypes

The typical onset is pediatric, adolescent, or young-adult. Most cases occur at 10–25 years, with a reported median age of 18. Symptoms often develop over only 2–4 weeks, reflecting rapid tumor growth. Abdominal pain occurs in approximately 87% and a palpable abdominal/pelvic mass in 85%. Possible manifestations include abdominal distension, nausea/vomiting, torsion or rupture, menstrual disturbance, precocious puberty or virilization from hormone-producing components, ascites, and symptoms from metastatic peritoneal, nodal, hepatic, or pulmonary disease. (saani2023clinicalchallengesin pages 2-3, saani2023clinicalchallengesin pages 1-2)

Suggested HPO annotations are Abdominal pain (HP:0002027), abdominal distention, pelvic mass, ovarian neoplasm, nausea and vomiting, ascites, menstrual irregularity, primary amenorrhea, elevated serum AFP, elevated serum β-hCG, and elevated serum LDH. Frequencies beyond pain and palpable mass are not robustly quantified.

Laboratory phenotype depends on histology:

• YST: AFP elevation is characteristic.
• Choriocarcinoma: β-hCG elevation.
• Embryonal carcinoma: AFP and/or β-hCG.
• Dysgerminoma: LDH may be elevated; a minority containing syncytiotrophoblast can produce β-hCG.
• Immature teratoma: AFP should prompt evaluation for a YST component, although modest elevations can occur.

A 2024 series of 16 female pelvic YSTs found AFP elevation in every patient and CA-125 elevation in 7/12 (58.33%). Thirteen of 16 lesions (81.25%) were ovarian. These data are useful but derive from a small referral cohort.

Quality-of-life burdens include acute pain, hospitalization, chemotherapy toxicity, fear of recurrence, altered body image and sexuality, premature ovarian insufficiency, and uncertainty about fertility. Fertility-sparing treatment improves reproductive opportunity, but formal EQ-5D, SF-36, or PROMIS estimates were not available in the retrieved ovarian-specific evidence. (saani2023clinicalchallengesin pages 5-6)

4. Genetic and molecular information

Somatic alterations

MOGCT is not usually a single-gene Mendelian disorder. Its defining molecular pattern is low somatic point-mutation burden with aneuploidy, copy-number imbalance, and epigenetic reprogramming. Recurrent alterations include:

• 12p gain or i(12p): a keystone feature of postpubertal malignant GCT. One series found 12p gain in 15/34 (44%) malignant tumors. In a pediatric multi-omic cohort, 12p gain occurred in 39%, and 40% of that group carried i(12p).
• Other recurrent gains include 20q, 21, 8, and 1q; chromosome 13 loss occurs in some tumors.
• KIT activating mutations, commonly exon 17, are enriched in dysgerminoma. In one 87-tumor landscape study, nonsynonymous KIT variants occurred in 4/24 sequenced cases (16.7%).
• KRAS/NRAS mutations occur less frequently; recurrent KRAS codon-12 variants have been reported.
• PIK3CA amplification occurred in 19/87 (21.8%) and AKT amplification in 18/87 (20.6%).
• YST studies report KRAS, KIT, occasional TP53, deletion of ARID1A/PARK2, and amplification of ZNF217, CDKN1B, and KRAS.
• Immature teratomas often have near-diploid genomes with extensive loss of heterozygosity but few or no recurrent somatic driver mutations. (pinto2023molecularbiologyof pages 7-9, pinto2023molecularbiologyof pages 9-11)

These are predominantly somatic alterations. Population allele frequencies are therefore not meaningful in the way they are for inherited disorders. Their presence does not currently mandate routine germline testing. Germline karyotyping or DSD-focused testing is appropriate when there is primary amenorrhea, absent puberty, virilization, bilateral dysgenetic gonads, Turner mosaicism, or other syndromic findings.

Epigenetics, transcriptomics, and noncoding RNA

Dysgerminoma/germinoma is globally hypomethylated and retains pluripotency expression. More differentiated YST, teratoma, and choriocarcinoma are relatively hypermethylated; embryonal carcinoma is intermediate. In 154 pediatric GCTs, 8,481 differentially methylated regions were identified, with dysgerminoma/germinoma showing reduced methylation in angiogenesis and immune pathways and YST showing tumor-suppressor hypermethylation. All eight ovarian GCTs in one IGF2/H19 study were hypomethylated at that imprinting-control region. (pinto2023molecularbiologyof pages 11-12)

YSTs overexpress endodermal programs such as GATA6 and FOXA2 and show WNT/β-catenin and TGF-β/BMP pathway enrichment. The miR-371–373 and miR-302–367 clusters are overexpressed across malignant GCT sites and histologies. Their clinical use in ovarian disease remains investigational; the strongest validation currently comes from testicular GCT, where miR-371a-3p reached 84.7% sensitivity and 99% specificity in one cited study. (pinto2023molecularbiologyof pages 9-11, pinto2023molecularbiologyof pages 12-13)

Suggested annotations

• GO biological processes: primordial germ-cell development; germ-cell migration; DNA methylation/demethylation; genomic imprinting; regulation of cell proliferation; MAPK cascade; PI3K–AKT signaling; Wnt signaling; BMP signaling; epithelial-to-mesenchymal transition; nucleotide-excision repair; apoptotic process.
• Cell Ontology: primordial germ cell; oogonium; oocyte; ovarian germ cell; tumor cell; peritoneal mesothelial cell; immune cell.
• GO cellular components: nucleus, chromatin, chromosome, plasma membrane, receptor tyrosine-kinase complex, mitotic spindle.

5–6. Environment and pathophysiology

The principal causal chain is:

1. Upstream developmental vulnerability: primordial germ cells undergo migration, imprint erasure, and global epigenetic reprogramming.
2. Persistence of an immature/pluripotent state: OCT3/4, NANOG, SOX factors, KIT/KITLG, and related programs support survival rather than normal differentiation.
3. Genomic/epigenomic change: 12p gain, aneuploidy, KIT or RAS activation, PI3K–AKT amplification, imprinting defects, and histology-specific methylation alter proliferation and lineage commitment.
4. Histologic divergence: germinoma-like cells produce dysgerminoma; endodermal differentiation produces YST; pluripotent somatic differentiation produces teratoma; mixed differentiation produces mixed tumors.
5. Downstream behavior: rapid proliferation causes a large ovarian mass, pain, rupture/torsion, and peritoneal or nodal dissemination. AFP, β-hCG, and LDH reflect lineage and tumor burden.
6. Treatment response/resistance: cisplatin DNA adducts normally trigger apoptosis. Resistance can involve nucleotide-excision repair, TP53-pathway change, cancer-stem-cell programs, EMT, and detoxification. OVOL2 overexpression correlates with resistant YST; in NOY1-CR cells, GSTA1, ABCG2, CD133, and ALDH programs were increased. (pinto2023molecularbiologyof pages 16-18, pinto2023molecularbiologyof pages 13-15, pinto2023molecularbiologyof pages 15-16)

Immune involvement is incompletely characterized. Dysgerminomas often contain conspicuous lymphocytes and show immune-pathway epigenetic differences, but no ovarian-specific immune biomarker currently selects checkpoint therapy. Proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, and CRISPR-screen evidence is too sparse for routine annotation. (saani2023clinicalchallengesin pages 8-9, pinto2023molecularbiologyof pages 11-12)

7. Anatomical structures

The primary organ is the ovary—suggested UBERON term ovary (UBERON:0000992)—usually one ovary. Bilaterality occurs in approximately 10–15% of pure dysgerminomas and 5–10% of mixed tumors; bilateral YST and immature teratoma are uncommon. Secondary sites include pelvic and abdominal peritoneum, omentum, retroperitoneal lymph nodes, liver, and lung. (pinto2023molecularbiologyof pages 4-6, saani2023clinicalchallengesin pages 2-3)

Relevant tissues/cells are ovarian parenchyma and germ-cell lineage, with tumor-associated stroma, vasculature, lymphocytes, and peritoneal mesothelium. At subcellular level, the nucleus/chromatin and chromosomes are central because copy-number and epigenetic abnormalities dominate.

8–9. Temporal development, inheritance, and population

MOGCT commonly has acute/subacute presentation and rapid progression, not a long premalignant symptomatic phase. Approximately 60–70% present at an early stage. FIGO ovarian staging is used: stage I is confined to ovaries/fallopian tubes; II involves pelvic extension; III includes extrapelvic peritoneal or retroperitoneal nodal disease; IV denotes distant metastasis. Most relapses occur in the first two years, frequently in peritoneal or retroperitoneal nodal sites. (saani2023clinicalchallengesin pages 3-5, saani2023clinicalchallengesin pages 5-6)

MOGCTs account for approximately 2–5% of ovarian cancers. The 2023 review gives a global incidence near 4 per million women per year; its separate “4 per 100,000” estimate appears internally inconsistent and should not be combined with the per-million estimate without checking the underlying source. Higher proportional frequencies have been reported in Asian and African populations and in Saudi Arabia—13.8% of ovarian tumors versus approximately 5% in Western series—but proportions are affected by the younger population structure and referral patterns. (saani2023clinicalchallengesin pages 2-3, saani2023clinicalchallengesin pages 1-2)

The usual inheritance pattern is sporadic/multifactorial, with no established penetrance, anticipation, carrier frequency, founder variant, or germline-mosaicism model. DSD-associated risk follows the underlying condition—for example, 46,XY gonadal dysgenesis or mosaic Y-chromosome material—not an inheritance pattern intrinsic to MOGCT.

10. Diagnosis

Clinical work-up

A rapidly enlarging adnexal mass in a child or young adult should prompt:

1. Pelvic/abdominal ultrasonography with Doppler.
2. Serum AFP, β-hCG, LDH, complete blood count, renal and hepatic function; CA-125 can assist but is nonspecific.
3. Contrast-enhanced abdominal/pelvic CT or MRI for extent; chest imaging for metastases. PET is selective, not routine.
4. Fertility and endocrine assessment before treatment where feasible.
5. Histopathologic confirmation and FIGO staging. (saani2023clinicalchallengesin pages 2-3)

YSTs are often solid or mixed solid-cystic, highly vascular masses. A 2024 cohort described rapid enhancement, rich low-resistance arterial flow, and a “fissure sign,” but these are supportive rather than diagnostic.

Pathology and immunohistochemistry

Useful panels include:

• Broad germ-cell marker: SALL4.
• Dysgerminoma: OCT3/4, SALL4, SOX17, D2-40, KIT/CD117; typically AFP-negative.
• YST: AFP, glypican-3, SALL4; Schiller–Duval bodies and hyaline globules are classic.
• Embryonal carcinoma: OCT3/4, SALL4, CD30, cytokeratin.
• Choriocarcinoma: β-hCG in syncytiotrophoblast.
• Immature teratoma: immature neuroepithelial rosettes/tubules; thorough sampling is essential.

Chromosome-12p FISH may support a malignant postpubertal GCT but is not required in every classic case. (saani2023clinicalchallengesin pages 2-3)

Differential diagnoses include benign mature cystic teratoma, epithelial ovarian carcinoma, sex-cord stromal tumor, small-cell carcinoma of hypercalcemic type, lymphoma, metastatic carcinoma, gestational choriocarcinoma, and pregnancy. Gestational versus nongestational choriocarcinoma may require clinical history and genotyping.

Routine WES/WGS, methylation profiling, or liquid biopsy is not standard. Tumor sequencing is reasonable in relapsed/refractory disease or research protocols; karyotype and targeted DSD testing are indicated when phenotype suggests gonadal dysgenesis. No population screening test exists.

11. Outcomes and prognosis

Early-stage survival is approximately 82–100%; late-stage survival is near 75% in compiled series. Stage I disease has about 90% long-term disease-free survival. Dysgerminoma is exceptionally chemotherapy-sensitive. Adverse factors include advanced stage, residual disease, older/postmenopausal age, YST histology, slow or incomplete tumor-marker decline, platinum resistance, and relapse. Stage IV ovarian GCT in patients aged at least 11 years has been reported to have under 70% long-term disease-free survival. More than half of patients with relapsed YST may die from disease. (saani2023clinicalchallengesin pages 3-5, pinto2023molecularbiologyof pages 16-18, pinto2023molecularbiologyof pages 6-7)

Long-term morbidity is often treatment-related: bleomycin pulmonary toxicity; cisplatin nephrotoxicity, ototoxicity, neuropathy and cardiovascular/metabolic risk; etoposide-related myelosuppression and rare therapy-related leukemia; infertility or premature ovarian insufficiency; and psychosocial/sexual effects.

Fertility outcomes are generally favorable after conservative treatment. One cohort reported pregnancy in 42/45 women, yielding 65 pregnancies and 56 births among 40 survivors; another reported 33 uneventful pregnancies among 31/39 patients. Across studies, 75.6% retained regular menstruation and pregnancy rates ranged from 18.8% to 55.7%, though denominators and attempts to conceive varied. (saani2023clinicalchallengesin pages 3-5, saani2023clinicalchallengesin pages 5-6)

12. Treatment and current applications

Standard algorithm

• Stage IA dysgerminoma: unilateral salpingo-oophorectomy (USO), staging, and surveillance. Surgery-only recurrence is approximately 15–25%, but relapse is usually salvageable.
• Stage IA grade-1 immature teratoma: USO, staging, surveillance.
• Grade 2–3 stage-I immature teratoma: surveillance versus 3–4 cycles BEP remains controversial; pediatric practice is more surveillance-oriented.
• Stage-I YST or incompletely staged/marker-positive disease: generally postoperative BEP; surveillance after completely staged, marker-negative disease is investigational and not universally accepted.
• Stages II–IV: fertility-sparing cytoreduction when feasible followed by 3–4 cycles BEP. Extensive mutilating surgery should be avoided because of chemosensitivity. EP may be used when bleomycin is unsuitable, particularly in older patients. (saani2023clinicalchallengesin pages 6-8, saani2023clinicalchallengesin pages 5-6, pinto2023molecularbiologyof pages 6-7)

BEP comprises bleomycin, etoposide, and cisplatin. Suggested NCI Thesaurus intervention concepts are unilateral salpingo-oophorectomy, fertility-sparing surgery, tumor-debulking surgery, BEP regimen, EP regimen, active surveillance, and autologous hematopoietic stem-cell transplantation. Chemotherapy agents should also be annotated individually; cisplatin is a platinum coordination compound and etoposide a topoisomerase-II inhibitor.

Relapse and refractory disease

Options include complete resection of operable residual disease and salvage TIP (paclitaxel/ifosfamide/cisplatin), VeIP (vinblastine/ifosfamide/cisplatin), or high-dose TI-CE with autologous stem-cell rescue. Evidence is mostly extrapolated from testicular GCT. Growing teratoma syndrome—enlarging masses during/after chemotherapy with normalized markers and mature teratoma histology—is chemotherapy-resistant and requires complete surgical resection. (saani2023clinicalchallengesin pages 6-8)

Targeted agents remain experimental. Everolimus, imatinib, sunitinib, and pazopanib produced only 0–13% response rates in recurrent GCT series. Brentuximab vedotin produced responses in 2/9 patients. Pembrolizumab and avelumab studies in predominantly male refractory GCT have not shown convincing benefit; these cannot be assumed effective in ovarian disease. (saani2023clinicalchallengesin pages 6-8, saani2023clinicalchallengesin pages 8-9)

Recent trial development

NCT02429687/MOGCT-01, a randomized open-label phase III Chinese study, compares paclitaxel 175 mg/m² plus carboplatin AUC 5–6 every 21 days for 4–6 cycles against BEP for 3–4 cycles. Estimated enrollment is 129; outcomes include five-year progression-free survival, overall survival, response, and toxicity. The registry was updated April 25, 2023 and listed estimated primary completion in May 2025 and completion in 2030. Importantly, the retrieved eligibility field inconsistently described sex-cord stromal histologies despite the title and intervention summary specifying MOGCT; eligibility should therefore be verified directly before referral: https://clinicaltrials.gov/study/NCT02429687. (NCT02429687 chunk 1)

13. Prevention

There is no established primary prevention for sporadic MOGCT, no vaccine, and no population-based ovarian screening program. Secondary prevention consists of rapid evaluation of symptoms and longitudinal marker/imaging surveillance after treatment.

The principal risk-directed primary prevention is prophylactic bilateral gonadectomy for high-risk dysgenetic gonads, especially confirmed 46,XY complete gonadal dysgenesis. In lower-risk DSD groups, timing should be individualized through multidisciplinary endocrine, genetics, gynecology, pathology, fertility, and psychosocial counseling. Ultrasound/MRI cannot reliably exclude early gonadal neoplasia, and no liquid biomarker has sufficient validation to replace histologic risk management. (lu2022gonadaltumorrisk pages 7-8, sowinskaprzepiera2023latediagnosisof pages 1-2)

Tertiary prevention includes fertility counseling and cryopreservation where feasible, pulmonary/renal/auditory monitoring during BEP, avoidance of unnecessary radical surgery, structured surveillance for early relapse, and long-term survivorship care.

14–15. Other species and model systems

No well-validated naturally occurring veterinary disease was found that is sufficiently characterized to serve as a direct homolog of human MOGCT; zoonotic transmission is not applicable. Germ-cell developmental pathways are evolutionarily conserved, but spontaneous ovarian GCTs in companion animals should not be treated as equivalent without comparative pathology and molecular confirmation.

Available experimental systems are limited:

• NOY1/NOY2 human ovarian YST cell lines; NOY1-CR was generated by 12 months of stepwise cisplatin exposure and became 22.3-fold more resistant. GSTA1 inhibition restored cisplatin sensitivity.
• TC587, derived from a 12-year-old with ovarian YST, expresses AFP and SALL4 and carries NRAS, KIT, KMT2C, RSF1, and TP53 alterations.
• Three-dimensional spheroids and quail chorioallantoic-membrane assays model invasion and micrometastasis.
• Immunodeficient-mouse xenografts reproduce tumor formation but lack an intact human immune microenvironment.
• A pediatric ovarian-YST PDX reportedly mirrored clinical response to bleomycin/etoposide/cisplatin; nevertheless, no broad, well-validated ovarian-GCT PDX panel or organoid biobank exists. (pinto2023molecularbiologyof pages 13-15, pinto2023molecularbiologyof pages 15-16)

These models are useful for cisplatin resistance, stemness, and candidate-drug testing but incompletely capture developmental origin, histologic diversity, host immunity, fertility effects, and patient-to-patient heterogeneity.

Evidence limitations and authoritative interpretation

The most authoritative recent ovarian-specific reviews emphasize that rarity has produced small, retrospective, histologically mixed cohorts and substantial extrapolation from testicular GCT. Apparent genomic frequencies can therefore vary by age and subtype. Molecular findings such as KIT, PI3K, methylation, and miR-371–373 are biologically compelling but are not yet routine predictive biomarkers. The central expert consensus is consequently conservative: preserve fertility whenever oncologically safe, use histology/stage/marker kinetics rather than unvalidated sequencing to guide first-line care, avoid overtreatment of low-risk stage-I disease where surveillance is supported, and refer recurrent disease to a specialist GCT center or clinical trial. (pinto2023molecularbiologyof pages 7-9, pinto2023molecularbiologyof pages 1-3, pinto2023molecularbiologyof pages 16-18)

Principal recent sources

• Pinto MT et al. Molecular Biology of Pediatric and Adult Ovarian Germ Cell Tumors: A Review. Cancers. Published May 29, 2023. DOI: https://doi.org/10.3390/cancers15112990. (pinto2023molecularbiologyof pages 4-6)
• Saani I et al. Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours. International Journal of Environmental Research and Public Health. Published June 15, 2023. DOI: https://doi.org/10.3390/ijerph20126089. (saani2023clinicalchallengesin pages 3-5)
• Lu L et al. Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and Y chromosomal constitution. Frontiers in Pediatrics. Published July 2022. DOI: https://doi.org/10.3389/fped.2022.856128. (lu2022gonadaltumorrisk pages 1-2)
• Berek JS et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International Journal of Gynecology & Obstetrics. Published October 2021. DOI: https://doi.org/10.1002/ijgo.13878. (berek2021cancerofthe pages 17-18)

PMIDs were not reliably exposed in the retrieved full-text metadata and therefore are not fabricated here; DOI URLs are supplied for source resolution.

References

1. (pinto2023molecularbiologyof pages 4-6): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.

2. (saani2023clinicalchallengesin pages 2-3): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 87 citations.

3. (pinto2023molecularbiologyof pages 1-3): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.

4. (pinto2023molecularbiologyof pages 16-18): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.

5. (saani2023clinicalchallengesin pages 1-2): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 87 citations.

6. (saani2023clinicalchallengesin pages 5-6): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 87 citations.

7. (saani2023clinicalchallengesin pages 3-5): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 87 citations.

8. (pinto2023molecularbiologyof pages 9-11): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.

9. (pinto2023molecularbiologyof pages 11-12): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.

10. (pinto2023molecularbiologyof pages 12-13): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.

11. (pinto2023molecularbiologyof pages 6-7): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.

12. (saani2023clinicalchallengesin pages 6-8): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 87 citations.

13. (NCT02429687 chunk 1): Beihua Kong. TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors. Beihua Kong. 2015. ClinicalTrials.gov Identifier: NCT02429687

14. (saani2023clinicalchallengesin pages 8-9): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 87 citations.

15. (pinto2023molecularbiologyof pages 13-15): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.

16. (pinto2023molecularbiologyof pages 15-16): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.

17. (NCT02429687 chunk 2): Beihua Kong. TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors. Beihua Kong. 2015. ClinicalTrials.gov Identifier: NCT02429687

18. (lu2022gonadaltumorrisk pages 6-7): Liangsheng Lu, Feihong Luo, and Xiang Wang. Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and y chromosomal constitution with different genetic etiologies. Frontiers in Pediatrics, Jul 2022. URL: https://doi.org/10.3389/fped.2022.856128, doi:10.3389/fped.2022.856128. This article has 16 citations.

19. (lu2022gonadaltumorrisk pages 1-2): Liangsheng Lu, Feihong Luo, and Xiang Wang. Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and y chromosomal constitution with different genetic etiologies. Frontiers in Pediatrics, Jul 2022. URL: https://doi.org/10.3389/fped.2022.856128, doi:10.3389/fped.2022.856128. This article has 16 citations.

20. (lu2022gonadaltumorrisk pages 5-6): Liangsheng Lu, Feihong Luo, and Xiang Wang. Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and y chromosomal constitution with different genetic etiologies. Frontiers in Pediatrics, Jul 2022. URL: https://doi.org/10.3389/fped.2022.856128, doi:10.3389/fped.2022.856128. This article has 16 citations.

21. (sowinskaprzepiera2023latediagnosisof pages 1-2): Elżbieta Sowińska-Przepiera, Mariola Krzyścin, Adam Przepiera, Agnieszka Brodowska, Ewelina Malanowska, Mateusz Kozłowski, and Aneta Cymbaluk-Płoska. Late diagnosis of swyer syndrome in a patient with bilateral germ cell tumor treated with a contraceptive due to primary amenorrhea. International Journal of Environmental Research and Public Health, 20:2139, Jan 2023. URL: https://doi.org/10.3390/ijerph20032139, doi:10.3390/ijerph20032139. This article has 6 citations.

22. (piazza2019germcelltumors pages 1-2): Mauri José Piazza and Almir Antonio Urbanetz. Germ cell tumors in dysgenetic gonads. Clinics, 74:e408, Nov 2019. URL: https://doi.org/10.6061/clinics/2019/e408, doi:10.6061/clinics/2019/e408. This article has 37 citations and is from a peer-reviewed journal.

23. (piazza2019germcelltumors pages 4-5): Mauri José Piazza and Almir Antonio Urbanetz. Germ cell tumors in dysgenetic gonads. Clinics, 74:e408, Nov 2019. URL: https://doi.org/10.6061/clinics/2019/e408, doi:10.6061/clinics/2019/e408. This article has 37 citations and is from a peer-reviewed journal.

24. (lanciotti2019differentclinicalpresentations pages 3-5): Lucia Lanciotti, Marta Cofini, Alberto Leonardi, Mirko Bertozzi, Laura Penta, and Susanna Esposito. Different clinical presentations and management in complete androgen insensitivity syndrome (cais). International Journal of Environmental Research and Public Health, 16:1268, Apr 2019. URL: https://doi.org/10.3390/ijerph16071268, doi:10.3390/ijerph16071268. This article has 126 citations.

25. (pinto2023molecularbiologyof pages 7-9): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.

26. (lu2022gonadaltumorrisk pages 7-8): Liangsheng Lu, Feihong Luo, and Xiang Wang. Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and y chromosomal constitution with different genetic etiologies. Frontiers in Pediatrics, Jul 2022. URL: https://doi.org/10.3389/fped.2022.856128, doi:10.3389/fped.2022.856128. This article has 16 citations.

27. (berek2021cancerofthe pages 17-18): Jonathan S. Berek, Malte Renz, Sean Kehoe, Lalit Kumar, and Michael Friedlander. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International Journal of Gynaecology and Obstetrics, 155:61-85, Oct 2021. URL: https://doi.org/10.1002/ijgo.13878, doi:10.1002/ijgo.13878. This article has 726 citations.

Artifacts

• Edison artifact artifact-00